Parkwalk closes DefiniGEN investment for the University of Cambridge Enterprise Fund II
DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.
The Company provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.
